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Objectives: In routine clinical practice the selection of a particular anticoagulant 
for treatment of a specific patient may be based on a variety of different factors. The 
aim of this study was to explore if there were differences in the characteristics of 
patients with non-valvular atrial fibrillation (NVAF) who started on dabigatran etex-
ilate (DE) and who in the prior year had no oral anticoagulant treatment (initiators) 
versus those who had previously been treated with warfarin (switchers). MethOds: 
Medco claims data were used to characterize 7,055 NVAF patients from the US with 
a DE prescription between Feb 2011 and Apr 2012. The first prescription in this 
period defined the index date. The treatment-groups were stratified by initiators 
and switchers. Characteristics, comedications, and comorbidities in the 12-month-
period prior to index date were assessed. All illustrated differences were statistically 
significant (p < 0.05) (1). Results: Switchers (N = 2,585) had a mean age of 74.0 
(±9.6) years, whereas initiators (N= 1,903) were younger (mean 70.0 (±9.6) years). 
A higher proportion of switchers used comedications compared to initiators, e.g. 
beta blockers (66% vs. 59%), and gastrointestinal drugs (34% vs. 28%). Switchers 
were more likely to have congestive heart failure, hypertension, cerebrovascular 
disease, renal disease and bleeding related hospitalizations when compared to the 
initiators, and also had a higher mean CHA2DS2-VASc score (4.0 (±1.8) compared to 
initiators (3.4 (±1.9)). cOnclusiOns: This study shows differences between patients 
who are initiating DE as first anticoagulant treatment and those who are switched 
from warfarin to DE revealing that switchers might represent a distinct patient 
population. Identifying, stratifying or accounting for such differences are necessary 
in comparisons using real world data. (1) Schoof N et al., Characteristics of patients 
with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr 
Med Res Opin. 2013 Dec 27.
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Objectives: In 2011, various legislative measures were adopted in Slovakia regarding 
drug policy. The aim of the submitted work is to evaluate links between the introduc-
tion of regulations and the consumption of antihypertensive drugs (AH), expendi-
tures and patient co-payments. MethOds: We evaluated data on drugs consumption 
based on IMS Data. Patient co-payments data were taken from the National Health 
Information database. When evaluating the average amount of co-payments, we 
applied a weighted average, which takes into account the level of co-payment and 
consumption. Results: The consumption of AH (in DOT) increased continually in 
2006-2013 (+36%) and the turnover of AH dropped by 4% as a consequence of introduc-
ing new regulations. The impact of new regulations was expressed foremost in the 
consumption of RAS inhibitors, where the decrease in turnover after introduction of 
clusters in 2012 was 14%. In the evaluated period, the final price of AH was reduced 
by 35% (from € 8.86 to € 5.78) and the reimbursement was reduced by 52% (from € 7.87 
to € 3.76). At the same time, there was an increase in average co-payments by 105% 
(from € 0.99 to € 2.03). In the evaluated period, the patient co-payment for a fixed 
AH almost quadrupled (from € 1.05 to € 4.05). The patient paid an average of € 0.93 
more for one pack of fixed AH than for a free combination. After the introduction of 
regulations, the consumption of fixed combinations grew at a slower pace than in 
the case of monocomponents. cOnclusiOns: The legislative changes in drug policy 
had a significant impact on the consumption of antihypertensive drugs and on the 
expense of hypertension treatment. It is necessary to monitor long-term and analyse 
the impacts of regulations on the prescription of AH and to evaluate factors that can 
influence the success of hypertension treatment.
PCV155
initiation oF oral antiCoagUlant DrUgs: iDentiFiCation oF DriVers 
oF PresCribing oF neW agents VersUs WarFarin
Spillane S.1, Bennett K.2, Barry M.1
1HSE Medicines Management Programme, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland
Objectives: Oral anticoagulants (OACs), used for stroke prevention in atrial fibril-
lation, include warfarin and the newer drugs (NOACs) dabigatran, rivaroxaban and 
apixaban. High direct drug costs of the NOACs to the health care payer prompt 
monitoring of real-world NOAC uptake patterns. This study aimed to identify factors 
associated with anticoagulation initiation with NOACs versus warfarin. MethOds: 
Analyses were performed using national pharmacy claims data from a means-tested 
state medical services scheme. First-time initiators of an oral anticoagulant between 
January 2009 and December 2013 with ≥ 1 year scheme eligibility and ≥ age 50 
were identified. Patients whose claims amounted to < 90 days of oral anticoagula-
tion were excluded. Patient characteristics, and number and type of concomitant 
medications at the time of first oral anticoagulant were recorded and considered 
as predictors of NOAC initiation using multivariate logistic models (odds ratios, OR 
and 95% CIs). Results: 34,944 new initiators of oral anticoagulants were included. 
In 2009, 7.6% of new initiators received a NOAC; this figure rose to 41.2% in 2013. The 
following were positively associated with NOAC initiation in multivariate analyses: 
female gender (OR: 1.14,95% CI 1.07-1.21), age < 80 (OR: 1.11, 95% CI 1.04-1.19) and 
concomitant receipt of NSAID drugs (OR: 4.04, 95% CI 3.72-4.38). Receipt of multiple 
concomitant medications was negatively associated with NOAC initiation; patients 
receiving 15+ drug classes had a 42% decreased odds of NOAC receipt (versus ≤ 5 
drug classes) (OR: 0.58, 95% CI 0.51-0.66). Specific concomitant drugs negatively 
Objectives: Pharmaceutical expenditure accounted for between 11% to 13% of total 
health expenditure in European countries including Sweden in 2010 whereas this 
was 20% in Japan for the same year. We expect that big changes in sales pattern will 
happen as a result of patent expiry. Other changes have been seen when prescrib-
ers get negative/positive information on drugs. In this article we study the impact 
of patent expiry and negative information relating to pharmaceutical policies on 
pharmaceutical sales patterns of selected drugs in Sweden and Japan. MethOds: 
we selected angiotensin-converting enzyme inhibitors (ACEs) and Angiotensin 
Ⅱantagonists (ARBs), since widely used in Sweden and Japan. Seasonal autoregres-
sive integrated moving average (ARIMA) modeling with intervention analysis was 
used to estimate the change of sales volume. Results: Losartan had a positive 
change (0.77650, p= 0.0068) in October 2010, Candesartan had a negative change 
(-0.50760, p= 0.0058) in July 2010. There were no significant differences in the sales 
volume of Losartan, Telmisartan, except for Candesartan in Japan (0.04868, p= 0.7995, 
-0.38547, p= 0.0880, and -1.21215, p= 0.001, respectively). In this study, we used a 
publication informed that Candesartan and Telmisartan had not reduced patients’ 
mortality by a journal July in 2009 as negative information. cOnclusiOns: We 
found that the sales pattern of selected drugs were changed by negative information 
and not by the expiry of their patents in Sweden. Whereas in Japan the negative 
situation for implementing generic substitution like the therapeutic substitution 
of Trandolapril and the possibility of switching from Candesartan to a combination 
drug was seen. Further assessment will be needed since factors associated with the 
changing use of drugs will be infinite.
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Objectives: From April 2013, the method of calculating the prescription rate 
of generic drugs in Japan was changed and protected brand name drugs were 
excluded from the denominator. In the case of Japan, which does not have a 
reference pricing system, it is thought that this will lead to a change in prescrip-
tions toward protected brand name drugs rather than drug substitution to generic 
drugs. The objective of this study is to clarify the trends in relation to the prescrip-
tion of generic drugs, through the use of administrative data on a nationwide 
level. MethOds: We used survey data from dispensing pharmacies from April 
2012 to March 2014. As a comparison, we used the prescription data of 1139 acute 
care hospitals in which incentive measures for drug substitution to generic drugs 
had not taken place during the same period. The medical products in question 
were drugs for diabetes and hypotensive drugs. For data analysis used SQL Server 
2008 R2 and R. Results: As the dispensing pharmacy receives additional compen-
sation based on the rate of generic drugs dispensed by that pharmacy in the most 
recent 3 months, the dispensing rate of generic drugs will have a direct impact 
on their business. The change in the method of calculating generic drugs has a 
major impact on the dispensing pharmacies, and in this study we have shown 
the possibility of dispensing pharmacies shifting more to protected brand name 
drugs. The dispensing rate of generic drugs by acute care medical facilities has 
always been low, and thus the impact of the change in calculation of the dispens-
ing ratio is correspondingly low. cOnclusiOns: The results of this study show 
that when encouraging drug substitution to generic drugs as a policy to reduce 
drug expenditure, it is necessary to consider measures in relation to the shift to 
protected brand name drugs.
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Objectives: The objectives of this research are to provide an overview of the recalls 
of cardiac implant medical devices in the last decade according to the different 
categories of cardiac implant medical devices and analyze the recall reasons. On the 
basis of this analysis, this research will provide recommendations on how to build 
a high quality implant registry. MethOds: A systematic search was performed 
focusing on regulatory bodies’ homepages from a range of middle and high-income 
countries with sufficient information on cardiac implant recalls and the related 
reasons. Data was extracted for the years 2004-2014 with the following criteria 
applied: cardiac implant medical device recalls and reasons for recall, i.e. harm 
or risk to patients excluding labeling or legal problems. Results: 11 countries 
have been included in the study: United States, Canada, Australia, New Zealand, 
PR China, China Hong Kong, UK, Germany, Ireland, Switzerland and Saudi Arabia. 
104 recall reports have been analyzed in total. The categories of cardiac implants 
include the following: Implantable Cardioverter Defibrillator (ICD) 40.4%; pacemaker 
14.4%; stent 14.4%; as well as Cardiac Resynchronization Therapy (CRT) 13.5%; 
leads 9.6% and replacement materials 7.7%. Referring to the recall reasons, 32.7% 
of the reports related to problems with the device battery; 30.7% of devices were 
recalled due to incorrect therapy delivery; 15.4% devices had software problems; 
15.4% devices had connection problems and 5.8% of devices did not deliver correct 
output data. cOnclusiOns: Due to the high-risk nature of cardiac implants medi-
cal devices and their high complication rates associated with considerable associ-
ated mortality, the traceability and transparency of safety hazards information are 
crucial. By analyzing the recall information including recall reasons and cardiac 
implants categories, important information is gained that can inform a high qual-
ity cardiac implant registry for monitoring the safety of cardiac implant patients.
